Upload
others
View
5
Download
0
Embed Size (px)
Citation preview
SỰ CẦN THIẾT PHÂN LOẠI CHẨN
ĐOÁN ĐỘT QUỴ NHỒI MÁU NÃO
CẬP NHẬT CÁC NGHIÊN CỨU MỚI
TỪ HỘI NGHỊ ĐỘT QUỴ HOA KỲ
& ĐỘT QUỴ CHÂU ÂU 2016
GS.TS Lê Văn Thính
BVBM-ĐHYHN
TS.BS Nguyễn Huy Thắng
BV115-TP HCM
STROKE CLASSIFICATION1
ENCHANTED2
ARUBA3
Outline
STROKE CLASSIFICATION
1.0 OCSP CLASIFICATION (BAMFORD)
TOAST CLASIFICATION
Phân Loại Đột Quỵ
4
Small vessel disease
Large artery disease
CÁC NGUYÊN NHÂN ĐỘT QUỴ
Cardioembolism
Stroke of undetermined etiology
30-40%
10-20%
30-40%
Uncommon cause of Stroke
Oxfordshire classification (OCSP)
Trial of Org 10172 in Acute Stroke
Treatment (TOAST)
6
Phân Loại Đột Quỵ Thiếu Máu
7
Toàn Bộ Tuần Hoàn Trước
Một phần Tuần Hoàn Trước
Tuần Hoàn Sau
Hội chứng NMN lổ khuyết
PHÂN LOẠI BAMFORD
8
9
Phân loại TOAST
10
Bệnh lý xơ vữa mạch máu lớn
Significant (>50%)
stenosis
Occlusion of a major
brain artery or
branch cortical
artery
Presumably due to
atherosclerosis
11
MFV 240cm/s
Thuyên tắc não do huyết khối từ tim
BN nữ, 37T, rung nhĩ, hẹp 2 lá
18
Atrial myxoma Thrombus of
the left ventricle
Small-artery occlusion (Lacune)
LS: H/c nhồi máu não lổ
khuyết, không có t/c vỏ não
T/C: Tiểu đường, THA
CT/MRI: bình thường, tổn
thương thân não hoặc
vùng dưới vỏ <1.5cm
Duplex/arteriography:
Không ghi nhận tắc hẹp
ĐM lớn ≥ 50%
Stroke of undetermined etiology
Các khảo sát cân lâm sàng không xác định
được nguyên nhân đột quỵ.
Chưa hoàn tất các khảo sát CLS
≥ 2 nguy cơ có thể là nguyên nhân của đột
quỵ
21
So Sánh 2 Phân Loại Đột Quỵ
25
MCA37%
ExCr ICA23%
BA9%
VA11%
InCr ICA7%
PCA7%
ACA6%
PROSAC
9 university hospitals
Using DWI and MRA
Throughout Korea
, 2008-2010
Distribution of symptomatic atherosclerotic
vascular lesions in 1,000 acute stroke patients
ICAS:ECAS = 7:3 Kim JS et al.
Stroke 2012
Risk factors – dyslipidemia, Mets
syndrome
Genes
Vascular tortuosity
Contamination
ICAS vs. ECAS
Limitations in resolution (often flow
dependent)
Artifact
Can not evaluate vessel wall
pathology
45-yr old man without risk factors -- Diagnosis ?
High resolution vessel wall MRI
Patients who visited AMC with
(1) unilateral MCA disease (≥50% stenosis or
occlusion), (2) were ≤55 years old and had no or
minimal (≤1) atherosclerotic risk factors (3)
suspected as having ICAS on MRA
We excluded patients with a confirmed diagnosis
HR-MRI performed
Ahn SH, Kim JS et al, Stroke 2015
Stroke mechanisms of ECAS
Mostly, artery to artery embolism
Vulnerable plaque, platelet aggregation
Inflammation
& Hemodynamic- not major stroke
Platelet aggregation ++
Perforator (branch)
occlusion
Artery to artery
embolism
Mechanisms of stroke in ICAS
In situ
Thrombotic
occlusion
Platelet aggregation ++
Kết Luận
•Trong chẩn đoán ĐQ, việc phân loại ĐQ là
rất quan trọng và cần thiết.
•Từ phân loại ĐQ, thầy thuốc có thể xác
định nguyên nhân và cơ chế của ĐQ, trên
cơ sở đó sẽ có lựa chọn điều trị thích hợp.
ENCHANTED
2.0Answer reliably efficacy and safety questions in acute IS
Compared to standard-dose (0.9 mg/kg) rtPA,
low-dose (0.6 mg/kg) i.v. rtPA
Proven medical reperfusion treatment for acute
ischaemic stroke within 4.5 hours of symptom onset,
butrisk of symptomatic intracerebral haemorrhage (ICH)
risk of early death
• Most regulatory authorities - approved dose 0.9mg/kg
• Japan approval - lower dose (0.6mg/kg)
• Variable dose in Asia – related to patient affordability
and clinician concern over ICH risk
37
Background – intravenous alteplaserecombinant tissue plasminogen activator - rtPA
38
Hypotheses - compared to standard-dose (0.9
mg/kg) rtPA, low-dose (0.6 mg/kg) i.v. rtPA is:
1. ‘non-inferior’ - clinical outcome (mRS 2-6) at 90-
days
2. safer - lower risk of major sICH?
Compared to guideline recommended BP control
(<185 mmHg systolic target before initiation of
rtPA),
is rapid intensive BP lowering (130-140 mmHg
SBP target):
3. superior - clinical outcomes (mRS 2-6) at 90-days
Dual aims: to answer reliably efficacy and
safety questions in acute ischaemic stroke
ENCHANTED clinical network
Australia (4 sites)
Chile (4 sites)
China (27 sites) + Hong Kong (1 site)
Brazil (6 sites)
United Kingdom (26 sites)
39
Colombia (2 sites)
Norway (1 site)
Italy (3 sites)
Vietnam (6 sites)
Taiwan (8 sites)
Thailand (1 site)
S Korea (12 sites)
Singapore (1 site)
In thrombolysis-eligible patients with acute ischaemic
stroke, lower dose (0.6mg/kg) dose rtPA :
• Not shown to be noninferior to standard-dose (0.9
mg/kg) for primary outcome (conventional binary 0-1 vs 2-6
mRS)
• Shown to be noninferior to standard-dose (0.9mg/kg) with
respect to global functional outcome (shift on mRS)
• Comparable EQ-5D and all other clinical measures
• Caused fewer deaths, less ICH, and less fatal ICH
• Consistency of findings in all pre-specified subgroups
40
Major findings of ENCHANTED
In thrombolysis-eligible acute ischaemic stroke
patients, low-dose rtPA:
• Is safer - fewer symptomatic or fatal ICH, and fewer
deaths
• Is non-inferior (ie equally effective) for global functional
recovery (shift), both ITT and PP
Low-dose alteplase to be seriously considered for all
patients with acute ischaemic stroke considered at high
risk of ICH, regardless of age, ethnicity and severity
41
Implications for Clinicians
3.0Compare best possible AVM eradication
vs Medical management alone
A Randomized trial of Unruptured Brain AVMsFive-year Results
43
•BN nữ, 35 tuổi, nhập viện vì co giật.
•Được chẩn đoán AVM 3cm vùng đính P, “có
nguy cơ vỡ rất cao”.
•Được can thiệp “thành công” bằng kỹ thuật
can thiệp nội mạch
Author | 00 Month Year44
A Randomized trial of Unruptured Brain AVMsFive-year Results
Stapf C1,2,3 Overbey JR4 Mohr JP1 Moskowitz AJ4 Vicaut E2 Parides MK4
for the international ARUBA Investigators
1 Stroke Center, Columbia University, New York, NY
2 Univ Paris Diderot – Sorbonne Paris Cité, Paris, France
3 CRCHUM, Université de Montréal, Montreal, QC, Canada
4 InCHOIR, lcahn Sch of Med at Mount Sinai, New York, NY
Christian Stapf, M.D.
Full Professor
Department of Neurosciences
Université de Montréal
Principal Scientist, CRCHUM
Attending Vascular Neurologist, CHUM
Brain Arteriovenous Malformations
Clinical issues:
• Hemorrhage
• Epilepsy
• Focal deficits
• Headaches
• Asymptomatic
Al-Shahi R & Stapf C, Practical Neurology, 2005
USA / Canada:
5000 new cases detected per year (mean age: 40 years)
3000 (60%) diagnosed unruptured
• Prospective
• Internet-based
– Real time
– Online Monitoring
• Randomized
– 1:1
– 400 patients planned
• NIH/NINDS
– Funding
– DSMB
• International
– Americas
– Europe
– Australasia
• Multidisciplinary
– Neurosurgery
– Neuroradiology
– Radiotherapy*
– Neurology
* Local or associated site
ARUBA
• International
– Americas
– Europe
– Australasia
• Prospective
• Internet-based
– Real time
– Online Monitoring
Standard of care
Best possible AVM eradication
versus
Medical management alone
Experimental study arm
ARUBA
Inclusion:
• Unruptured Brain AVM confirmed by MRI
• Age > 18 years
• Informed consent
Exclusion:
• Previous AVM hemorrhage
• Prior AVM treatment
• AVM considered untreatable for eradication
• …
ARUBA
Primary Endpoint:
Time to Death or Symptomatic Stroke
• Symptomatic Hemorrhage or Infarction
• CT / MRT
Secondary Endpoint:
Neurological Deficit
• Rankin Scale ≥ 2
• Status 5 years post randomization
ARUBA
Year 1 - 5 Year 6 - 10
20122007
n=226 55% mean follow-up 33·3 months
ARUBAA Randomized trial of Unruptured Brain AVMs
DSMB: April 15, 2013
Enrollment stopped!
Year 1 - 5 Year 6 - 10
20122007
n=226
n=110 Medical management
mean follow-up 50.4 months
n=116 Interventional treatment
ARUBAA Randomized trial of Unruptured Brain AVMs
2017
July 15, 2015
Data locked
ARUBAPatient baseline profiles (n=226 AVM patients)
ARUBA cohort
n=226
Demographics
Age (yrs), mean
Female gender
Clinical Presentation
Seizure
Asymptomatic
Mod. Rankin Score
mRS 0
mRS 1
44 (±12)
94 (42%)
97 (43%)
94 (42%)
108 (48%)
118 (52%)
Patient baseline profiles (n=226 AVM patients)
ARUBA
ARUBA cohort
n=226
Scotland1
n=204
Finland2
n=187
Demographics
Age (yrs), mean
Female gender
Clinical Presentation
Seizure
Asymptomatic
Mod. Rankin Score
mRS 0
mRS 1
44 (±12)
94 (42%)
47 (±16)
83 (41%)
36 (±15)*
80 (43%)
97 (43%)
94 (42%)
85 (42%)
101 (50%)
n.a.
n.a.
108 (48%)*
118 (52%)
26 (13%)
104 (51%)
n.a.
n.a.
1 Al-Shahi Salman R, et al. JAMA. 2014;311:1661-1669. 2 LaaksoA, et al. Neurosurgery. 2008;63:244-53.
* p<0.001
Patient baseline profiles (n=226 AVM patients)
ARUBA
ARUBA cohort
n=226
Scotland 1
n=204
Finland 2
n=187
AVM anatomy
bAVM size <3cm
Lobar location
Infratentorial location
Eloquent location
140 (62%) *
205 (91%)
13 (6%)
107 (47%)
95 (47%)
187 (92%)
7 (3%)
104 (51%)
41 (22%)
137 (73%) *
10 (5%)
n.a.
Spetzler-Martin I
Spetzler-Martin II
Spetzler-Martin III
Spetzler-Martin IV
Spetzler-Martin V
65 (29%) *
72 (32%) *
64 (29%)
23 (10%)
0
30 (15%)
51 (25%)
41 (20%)
18 (9%)
2 (1%)
13 (7%)
15 (27%)
61 (33%)
46 (25%) *
14 (8%) *
1 Al-Shahi Salman R, et al. JAMA. 2014;311:1661-1669. 2 LaaksoA, et al. Neurosurgery. 2008;63:244-53.
* p<0.001
Spetzler Martin Grading Scale
• Size of AVM
Small (<3 cm) 1
Medium (3-6 cm) 2
Large (>6 cm) 3
Location
Noneloquent site 0
1
Eloquent site*
Venouse drainage
Superficial 0
Deep 1
Primary outcome, n=226“As Randomized” (time to 1st stroke or death)
ARUBA
Primary outcome, n=226“As Randomized” (time to 1st stroke or death)
ARUBA
Primary outcome, n=226“As Randomized” (time to 1st stroke or death)
NNH: 5 (95% CI 3 - 13)
ARUBA
ARUBAOutcome per Randomization
(intention to treat)
Interventional Therapy
(N=116)
n %
41 35.3
Medical Management
(N=110)
n %
15 13.6
P Value
Symptomatic stroke or death <0.0001
Any incident stroke
Hemorrhagic
Ischemic
40
30
10
34.5 13
9
4
11.8 <0.0001
Any death
AVM-related
Not AVM-related
4
2
2
3.4 2
0
2
1.8 0.49
Outcome on Treatment **
(per protocol)
Interventional Therapy
(N=106)
n %
43 40.6
Medical Management
(N=120)
n %
13 10.8
P Value
Symptomatic stroke or death <0.0001
Any incident stroke
Hemorrhagic
Ischemic
42
29
13
39.6 11
10
1
9.2 <0.0001
Any death
AVM-related
Not AVM-related
4
2
2
3.8 2
0
2
1.7 0.33
** N=8 (3.5%) patients randomized to MM crossed over to IT.
N=15 (6.6%) patients randomized to IT never received therapy. N=3 suffered a stroke prior to the initiation of IT
ARUBAPrimary outcome, n=226
“As Treated” (time to 1st stroke or death)
ARUBA
• Primary outcome, n=226
• “As Treated” (time to 1st stroke or death)
• NNH: 3 (95% CI 2 - 6)
ARUBASecondary Outcome
Death or disability (mRS ≥2) at 5 years
ARUBASecondary Outcome
Death or disability (mRS ≥2) at 5 years
ARUBASecondary Outcome
Death or disability (mRS ≥2) at 5 years
38%
18%
ARUBASecondary Outcome
Death or disability (mRS ≥2) at 5 years
38%
18%
40%
17%
ARUBAHarm, n=226
Serious Adverse Events (as randomized)Event Type Interventional
(n=116)
Medical
(n=110)
p
N Rate per N Rate per
Events pat/year Events pat/year
Stroke
Any 52 11.0945 16 3.3338 <0.001
Hemorrhagic 39 8.3209 11 2.2920 <0.001
Ischemic 13 2.7736 5 1.0418 0.054
Focal Deficit*
Any 20 4.2671 3 0.6251 <0.001
Persistent 7 1.4935 1 0.2084 0.032
Reversible 13 2.7736 2 0.4167 0.004
Epileptic seizures 95 20.2688 68 14.1686 0.023
Headache episode 116 24.7493 111 23.1282 0.609
* unrelated to stroke, epilepsy
Primary outcome subgroup analyses (as randomized)
Medical management better Preventive intervention better
Primary outcome subgroup analyses (as randomized)
Medical management better Preventive intervention better
ARUBASecondary analyses: outcome by treatment modality
* Primary endpoint: Symptomatic stroke or death
** DocumentedAVM removal required cerebral angiography by study protocol. For n=16 (15%) patients, the
AVM status was unknown, n=43 (41%) had a documentedAVM remnant on last follow-up imaging.
Interventional treatment received
n=106 patients
Primary endpoint*
n (row %)
Documented AVM obliteration**
n (row %)
Cumulative treatment modalities
Any endovascular (n=66) 33 (50.0) 34 (51.5)
Any surgery (n=22) 9 (41.0) 21 (95.5)
Any radiotherapy (n=57) 21 (36.8) 12 (21.1)
ARUBASecondary analyses: outcome by treatment modality
** DocumentedAVM removal required cerebral angiography by study protocol. For n=16 (15%) patients, the
AVM status was unknown, n=43 (41%) had a documentedAVM remnant on last follow-up imaging.
Interventional treatment received
n=106 patients
Primary endpoint
n (row %)
Documented AVM obliteration**
n (row %)
Cumulative treatment modalities
Any endovascular (n=66) 33 (50.0) 34 (51.5)
Any surgery (n=22) 9 (41.0) 21 (95.5)
Any radiotherapy (n=57) 21 (36.8) 12 (21.1)
Monomodal treatment (n=68)
Endovascular (n=28) 14 (50.0) 14 (50.0)
Surgery (n=7) 2 (28.6) 7 (100.0)
Radiotherapy (n=33) 8 (24.2) 6 (18.2)
Multimodal treatment (n=38)
Endovascular and Surgery (n=14) 6 (42.9) 14 (100.0)
Endovascular and Radiotherapy (n=23) 12 (52.2) 6 (26.1)
Endovascular and Surgery and Radiothx (n=1) 1 (100.0) 0 (0.0)
ARUBA• First pragmatic management trial in patients diagnosed with
an unruptured brain AVM
• Data based on a representative study cohort.
• Bias (if any) favoring intervention.
ARUBALessons learnt:
1.Patients with unruptured brain AVMs are at risk for
stroke. Spontaneous annual hemorrhage rate: 2.1%
(95% CI: 1.0-3.9)
2.The risk increases with the initiation of interventional
therapy:
• Risk of death and stroke: by factor 4.5
• Risk of functional deficits : by factor 2.5
• No benefit for: Epilepsy, headaches
3.High risk across all treatment modalities and AVM
subgroups
ARUBA
• Largest effect ever seen in a primary stroke
prevention trial: Risk reduction of 78% (for stroke
and death)
• Treatment of choice available world-wide at low-cost
• Trial results should be systematically disclosed to
patients
ARUBA• Largest effect ever seen in a primary stroke prevention trial:
Risk reduction of 78% (for stroke and death)
• Treatment of choice available world-wide at low-cost
• Trial results should be systematically disclosed to patients
Conclusion:
• Based on current knowledge, preventive interventions for
unruptured AVMs
• may be dangerous: NNH = 5 (over 5 years)
• cannot be safely recommended
• should only be offered as part of a controlled clinical study
ARUBA• Largest effect ever seen in a primary stroke prevention trial:
Risk reduction of 78% (for stroke and death)
• Treatment of choice available world-wide at low-cost
• Trial results should be systematically disclosed to patients
Conclusion:
• Based on current knowledge, preventive interventions for
unruptured AVMs
• may be dangerous: NNH = 5 (over 5 years)
• cannot be safely recommended
• should only be offered as part of a controlled clinical study
.
Standard dose IV thrombolysis is still recommended for Asian stroke patients. Low-dose alteplase to be considered for all patients with acute ischaemic stroke considered at high risk of ICH
1
For unruptured AVMs, just do LESS for …
MUCH MORE2
Conclusion
“WITHOUT HEALTH,
THERE IS NO
HAPPINESS”
THOMAS JEFFERSON
THANK YOU FOR YOUR
ATTENTION !